|
Home > Articles
Lymphoma: Imaging in the Evaluation of Residual Masses
Abstract
In the management of patients with lymphoma, imaging is essential not only for diagnosis but also to define prognosis and treatment by staging. Imaging is also used to assess the response to treatment that may affect the treatment strategy: new chemotherapeutic drug combinations and autologous stem cell transplantation. These different therapies have increased the need for higher accuracy to assess the response to treatment. Standardised imaging response
criteria must be well known by radiologists involved in the management of patients with lymphoma. Criteria are mainly volumetric, and are obtained from CT scans. Functional imaging techniques have been shown to provide better information on the viability of residual masses than does CT assessment of size changes.
CT remains the main imaging technique to assess response to treatment based on volumetric international criteria. New functional imaging tools evaluating perfusion (CT and MRI), and particularly glucose uptake (PET), will probably play an important role in bringing additional information on the metabolism of lymphomatous masses.
Author
A Rahmouni, M Divine, S Kriaa, C Haïoun, M-C Anglade, and H Kobeiter
Contact Details
Corresponding address:
Departments of Radiology and Hematology,
Centre Hospitalo-Universitaire Henri Mondor,
Créteil,
France
Reference
ICIS Cancer Imaging Volume 2
DOI: 10.1102/1470-7330.2002.0008
Date Posted
31 July 2002
Open Access is provided for this article.
Screen PDF
Size
184.90 KB
Minimum Estimated Download Times
ADSL 2Mb/s (Broadband): |
1 second |
ADSL 512Kb/s (Broadband): |
2 seconds |
64 Kb/s (ISDN): |
23 seconds |
33.3 Kb/s (Typical Modem): |
44 seconds |
Print PDF
Size
33.89 KB
Minimum Estimated Download Times
ADSL 2Mb/s (Broadband): |
1 second |
ADSL 512Kb/s (Broadband): |
1 second |
64 Kb/s (ISDN): |
4 seconds |
33.3 Kb/s (Typical Modem): |
8 seconds |
|
